全文获取类型
收费全文 | 17752篇 |
免费 | 1015篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 224篇 |
儿科学 | 608篇 |
妇产科学 | 451篇 |
基础医学 | 2576篇 |
口腔科学 | 508篇 |
临床医学 | 1620篇 |
内科学 | 3234篇 |
皮肤病学 | 352篇 |
神经病学 | 1658篇 |
特种医学 | 745篇 |
外国民族医学 | 5篇 |
外科学 | 2392篇 |
综合类 | 80篇 |
一般理论 | 5篇 |
预防医学 | 1249篇 |
眼科学 | 484篇 |
药学 | 1217篇 |
中国医学 | 27篇 |
肿瘤学 | 1358篇 |
出版年
2023年 | 130篇 |
2022年 | 136篇 |
2021年 | 339篇 |
2020年 | 256篇 |
2019年 | 326篇 |
2018年 | 486篇 |
2017年 | 392篇 |
2016年 | 451篇 |
2015年 | 441篇 |
2014年 | 555篇 |
2013年 | 732篇 |
2012年 | 1108篇 |
2011年 | 1117篇 |
2010年 | 575篇 |
2009年 | 474篇 |
2008年 | 944篇 |
2007年 | 965篇 |
2006年 | 909篇 |
2005年 | 885篇 |
2004年 | 814篇 |
2003年 | 717篇 |
2002年 | 771篇 |
2001年 | 419篇 |
2000年 | 451篇 |
1999年 | 389篇 |
1998年 | 123篇 |
1997年 | 92篇 |
1996年 | 100篇 |
1994年 | 73篇 |
1992年 | 188篇 |
1991年 | 163篇 |
1990年 | 182篇 |
1989年 | 152篇 |
1988年 | 161篇 |
1987年 | 175篇 |
1986年 | 162篇 |
1985年 | 166篇 |
1984年 | 117篇 |
1983年 | 117篇 |
1982年 | 70篇 |
1979年 | 151篇 |
1978年 | 84篇 |
1977年 | 91篇 |
1975年 | 67篇 |
1974年 | 81篇 |
1973年 | 91篇 |
1972年 | 77篇 |
1971年 | 67篇 |
1970年 | 81篇 |
1968年 | 79篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献3.
4.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
5.
6.
7.
8.
9.
10.